Research and analysis

Invasive meningococcus capsular group B (MenB): preventing secondary cases

Benefits of offering vaccination in addition to antibiotic chemoprophylaxis to close contacts of cases in the household, educational setting, clusters and the wider community.

From:
Public Health England
Published
12 April 2014

This publication was withdrawn on

This document has been replaced with Meningococcal disease: guidance on public health management.

Documents

[Withdrawn] Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease

PDF, 1.22 MB, 34 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document provides information about preventing secondary cases of invasive meningococcal capsular group B (MenB) and sets out the benefits of offering vaccination in addition to antibiotic chemoprophylaxis.

Published 12 April 2014

Related content